Shionogi: Pipeline, Products, Performance, Potential

Date: March 22, 2010
Pages: 84
US$ 1,040.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Shionogi: Pipeline, Products, Performance, Potential
Shionogi operates in a number of business fields, and principal among these is its Pharmaceuticals segment. Within this business segment, Shionogi is active in the following therapeutic areas: Infectious Diseases, Metabolic Syndrome, Anticancer, Neurology, Allergy and Circulatory. As part of Shionogi’s Second Medium-Term Management Plan (which began in April 2005, and runs until fiscal 2010), the company is planning to focus research efforts specifically on the treatment of infections, pain and metabolic syndrome.

Within Japan, Shionogi is recognised as one of the leading antibiotics companies and in recent years, Flomox, Flumarin and Vancomycin have all maintained their positions as top sellers in their product categories. However, a contracting antibiotic market and increased competition have impacted negatively on sales. To address this issue Shionogi has developed and launched Finibax (September 2005), and licensed-in Bayer’s Avelox (launched in Japan in December 2005). The company has also revitalised its metabolic syndrome product range with the launches of Crestor and Irbetan, both of which are expected to vie for the position of Shionogi's top-selling product within our forecast period.

To ensure long-term growth, Shionogi has succeeded in developing an encouraging pipeline containing several promising candidate drugs, most notably duloxetine. As one of the smaller pharmaceutical companies in Japan, this has largely been achieved through in-licensing. Shionogi is concentrating resources in the three target areas of infection, pain and metabolic syndrome, with the aim of advancing at least five new chemical compounds to Phase II or more advanced stages by the end of fiscal 2009.

Shionogi has a limited global profile, but has achieved substantial success from out-licensing major products in overseas markets to maximise their sales values and utilise the marketing infrastructures of overseas companies. The US development of Finibax was conducted by Peninsula Pharmaceuticals (now acquired by Johnson & Johnson) and the product was launched during 2007. Shionogi now has the possibility of overseas expansion in the antibiotics field.

This new strategic analysis report Shionogi: Pipeline • Products • Performance • Potential, provides a complete and critical review of the company and includes unique and independent assessments and forecasts of key products. Buyers of the web edition receive online access for one year via an easy-to-use interface with fast navigation and a full text search facility. All formats are the same price.

A detailed and comprehensive overview of current financial position, company strategy, product and pipeline analysis.


Key product analysis and forecasting
Infectious Diseases
  Avelox (moxifloxacin)
  Finibax (doripenem)
  Flomox (cefcapene pivoxil)
  Flumarin (flomoxef sodium)
  Rapiacta (peramivir)
  Tamiflu (oseltamivir)
  Vancomycin (vancomycin hydrochloride)
  Imunace (recombinant interleukin-2)
  Claritin (loratadine)
  Pirespa (betamethasone)
Metabolic Syndrome
  Crestor (rosuvastatin calcium)
  Irebetan (irbesartan)
  Cymbalta (duloxetine)
  OxyContin (oxycodone)


A wealth of background and detail
A full 5-year financial performance assessment
Key corporate events
Key agreements
Subsidiaries and joint ventures
Skip to top

Allergan: Pipeline, Products, Performance, Potential US$ 1,040.00 Apr, 2009 · 80 pages
Biogen Idec: Pipeline, Products, Performance, Potential US$ 1,040.00 Jan, 2010 · 86 pages
Chugai: Pipeline, Products, Performance, Potential US$ 1,040.00 Oct, 2009 · 80 pages
Merck & Co: Pipeline, Products, Performance, Potential US$ 1,040.00 Nov, 2009 · 186 pages

Ask Your Question

Shionogi: Pipeline, Products, Performance, Potential
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: